Diagnosis and treatment of gastrointestinal stromal tumors: a study of 96 patients.
- Author:
Yue-liang LOU
1
;
Hua CHEN
;
Xie-liang ZHANG
;
Zhong-li ZHAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antigens, CD34; metabolism; Child; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; diagnosis; metabolism; pathology; surgery; Humans; Liver Neoplasms; secondary; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Omentum; surgery; Peritoneal Neoplasms; secondary; Proto-Oncogene Proteins c-kit; metabolism; Retrospective Studies; Survival Rate
- From: Chinese Journal of Oncology 2004;26(7):437-439
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the pathological diagnosis, surgical treatment and prognostic factors of gastrointestinal stromal tumors (GISTs).
METHODSThe clinicopathological data of operated 96 patients with GISTs were analyzed retrospectively. Expression of CD117, CD34, SMA and S-100 was determined by immunohistochemical methods.
RESULTSExpression of CD117, CD34, SMA and S-100 was 79.2% (76/96), 58.3% (56/96), 35.4% (34/96) and 9.4% (9/96). Benign tumor 23 and malignant 73. Of the malignant, the omentum was resected in 39 and the rest remained, of which the recurrent and metastatic rates were 5.1% and 26.5% (P < 0.05). The safety margin between the normal intestine and tumor was > 5 cm in 46 patients; while in the other 27 patients, it was < 5 cm. The recurrent and metastatic rates were 6.5% and 29.6% (P < 0.05), respectively. The 5-year survival rates of benign and malignant GISTs were 91.5% and 57.3% (P < 0.05).
CONCLUSIONThe application of immunohistochemical markers CD117 and CD34 are supplementary to pathological diagnosis. The adapting of rational primary treatment, including complete tumor resection and prophylactic omentectomy, is able to reduce the recurrence of GISTs.
